Company / SG&A per Share
Gilead Sciences SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$4.63
FY2025
5-year range
$3.49 / $4.89
FY2021-FY2025
Trend
-5.2%
vs FY2024
Sector context
#36 of 210
Health Care
What the data says
Gilead Sciences's sg&a per share of $4.63 is higher than 83% of companies in the Health Care sector (FY2025). SG&A per Share has fluctuated over the past 10 years, ranging from $2.10 in FY2016 to $4.89 in FY2024.
Based on SEC 10-K filings.
4.63 in FY2025 with a 5-year CAGR of +2.6%. Top quartile in the Health Care sector.
Increased from $4.21 to $4.63 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +4.1%
- 5-Year CAGR
- +2.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 210This company $4.63 Sector average $40.75
▼
-88.6% below sector average
Key checks
Key Insights
- In FY2025, sg&a per share decreased 5.2% year-over-year.
- Ranks #36 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2024.
- Lowest sg&a per share in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.63 | -5.2% |
| FY2024 | $4.89 | +16.2% |
| FY2023 | $4.21 | +2.4% |
| FY2022 | $4.11 | +17.6% |
| FY2021 | $3.49 | -14.1% |
| FY2020 | $4.07 | +34.5% |
| FY2019 | $3.02 | +16.4% |
| FY2018 | $2.60 | -0.7% |
| FY2017 | $2.62 | +24.7% |
| FY2016 | $2.10 | -8.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026